Mirae Asset Global Investments Co. Ltd. Sells 77,218 Shares of R1 RCM Inc. (NASDAQ:RCM)

Mirae Asset Global Investments Co. Ltd. decreased its stake in shares of R1 RCM Inc. (NASDAQ:RCM) by 25.5% during the fourth quarter, Holdings Channel reports. The firm owned 225,430 shares of the healthcare provider’s stock after selling 77,218 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in R1 RCM were worth $2,383,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RCM. Point72 Middle East FZE bought a new position in R1 RCM in the fourth quarter worth approximately $29,000. Captrust Financial Advisors raised its position in R1 RCM by 81.7% in the second quarter. Captrust Financial Advisors now owns 1,664 shares of the healthcare provider’s stock worth $35,000 after acquiring an additional 748 shares during the period. Headlands Technologies LLC bought a new position in R1 RCM in the third quarter worth approximately $36,000. ANTIPODES PARTNERS Ltd raised its position in R1 RCM by 429.5% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock worth $59,000 after acquiring an additional 4,561 shares during the period. Finally, Salem Investment Counselors Inc. bought a new position in R1 RCM in the fourth quarter worth approximately $61,000. Institutional investors own 61.10% of the company’s stock.

Insider Activity at R1 RCM

In other R1 RCM news, President John M. Sparby sold 10,046 shares of R1 RCM stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the completion of the transaction, the president now directly owns 265,986 shares of the company’s stock, valued at approximately $3,811,579.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 37.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have weighed in on RCM shares. Leerink Partnrs reiterated an “outperform” rating on shares of R1 RCM in a research report on Monday, February 26th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of R1 RCM in a research report on Wednesday, April 10th. Citigroup upgraded shares of R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Wednesday, March 20th. KeyCorp restated a “sector weight” rating on shares of R1 RCM in a research report on Wednesday, April 10th. Finally, SVB Leerink started coverage on shares of R1 RCM in a research report on Monday, February 26th. They set an “outperform” rating and a $14.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.87.

R1 RCM Stock Down 1.1 %

RCM opened at $12.02 on Friday. The company has a fifty day moving average of $12.70 and a 200 day moving average of $11.55. R1 RCM Inc. has a fifty-two week low of $8.87 and a fifty-two week high of $18.70. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.57.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.